Christina Kyriakopoulou | Policy Officer, Health Research Programmes
European Commission

Day 1 - Tuesday 28 October @ 09:10

Keynote panel: Looking ahead, what does the future hold for Europe’s Life Science Strategy and what does it mean for rare diseases?

-The global impact of U.S. changes – what opportunities could this mean for Europe and how can we make this an advantage for Europe?

-How will the pharmaceutical legislation and EU level changes affect rare disease investment, regulation, affordability and accessibility to patients?

-How can we ensure Europe’s R&D remains competitive, well-funded and sustainable?

-How should industry respond in order to keep innovating more therapies and to expedite the approval of new medicines? 

-How can each multi-stakeholder contribute to a more sustainable ecosystem? 

Fabienne Bartoli, Inspector General, French National Authority for Health

Christina Kyriakopoulou, Policy Officer, Health Research Programmes, European Commission

×

Christina Kyriakopoulou / Keynote panel: Looking ahead, what does the future hold for Europe’s Life Science Strategy and what does it mean for rare diseases?

Christina Kyriakopoulou, Policy Officer, Health Research Programmes,
European Commission

Christina Kyriakopoulou works as a Policy Officer at the Directorate General for Research and Innovation of the European Commission, Directorate People: Health and Society and the unit Health Innovations and Ecosystems. She holds a PhD in biochemistry and she held postdoctoral positions in...

CloseMore

Toon Digneffe, Head, Public Affairs & Public Policy, Europe & Canada, Takeda

×

Toon Digneffe / Keynote panel: Looking ahead, what does the future hold for Europe’s Life Science Strategy and what does it mean for rare diseases?

Toon Digneffe, Head, Public Affairs & Public Policy, Europe & Canada,
Takeda

Toon Digneffe is Head of Public Affairs and Partnerships Europe & Canada at Takeda. He has over 20 years’ experience in government affairs, communications, market access and patient advocacy at local, regional and global level.   Mr Digneffe has extensive experience in pharmaceutical...

CloseMore

Raymond Huml, Vice President, Rare Disease Strategy, Sciensus

×

Raymond Huml / Keynote panel: Looking ahead, what does the future hold for Europe’s Life Science Strategy and what does it mean for rare diseases?

Raymond Huml, Vice President, Rare Disease Strategy,
Sciensus

Dr. Raymond A. Huml is the Vice President of Rare Disease Strategy at Sciensus, with over 30 years in the healthcare and biopharmaceutical industries. A leader in rare disease research and global due diligence, he has driven nearly $3 billion in capital commitments. A prolific author and...

CloseMore

Moderator: Sophie Schmitz, Managing Partner, Partners4Access

Rosa Castro, Public Affairs Director, EURORDIS

×

Rosa Castro / Keynote panel: Looking ahead, what does the future hold for Europe’s Life Science Strategy and what does it mean for rare diseases?

Rosa Castro, Public Affairs Director,
EURORDIS

Rosa Castro joined EURORDIS in 2025 as Public Affairs Director. She supports the organisation’s public affairs strategy to advance policies that improve access to treatments for people living with rare diseases across Europe, working to address existing barriers and promote fairer, more coordinated ...

CloseMore